A peptide derived from melanocytic protein gp100 and presented by HLA-B35 is recognized by autologous cytolytic T lymphocytes on melanoma cells

Tissue Antigens

Volumn 65, Issue 2, 2005, Pages 156-162

  Vigneron, N ^a   Ooms, A ^b   Morel, Sandra ^a,c   Ma, W ^a   Degiovanni, G ^b   Van Den Eynde, Benoit J ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

CTL; gp100; HLA B35; Melanoma; Peptide

Indexed keywords

GLYCOPROTEIN GP 100; HLA B ANTIGEN; HLA B35 ANTIGEN; PEPTIDE; RNA;

ALLELE; ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; CELL DIFFERENTIATION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; HLA SYSTEM; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR IMMUNOLOGY;

AMINO ACID SEQUENCE; ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; CYTOTOXICITY, IMMUNOLOGIC; HLA-B35 ANTIGEN; HUMANS; MELANOCYTES; MELANOMA; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 14844314199     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2005.00365.x     Document Type: Article

References (30)

1. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994: 12: 337-65.
2. Brichard V, Van Pel A, Wolfel T et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993: 178: 489-95.
3. Wolfel T, Van Pel A, Brichard V et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994: 24: 759-64.
4. Cox AL, Skipper J, Chen Y et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994: 264: 716-9.
5. Kawakami Y, Eliyahu S, Sakaguchi K et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994: 180: 347-52.
6. Coulie PG, Brichard V, Van Pel A et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994: 180: 35-42.
7. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol 1996: 19: 81-4.
8. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998: 4: 321-7.
9. Kawakami Y, Eliyahu S, Jennings C et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995: 154: 3961-8.
10. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998: 4: 328-32.
11. Jager E, Maeurer M, Hohn H et al. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. Int J Cancer 2000: 86: 538-47.
12. Van den Eynde B, van der Bruggen P. Peptide database of T-cell defined tumor antigens. Cancer Immun 2001 (available from http://www.cancerimmunity.org/ peptidedatabase/Tcellepitopes.htm).
13. Kawakami Y, Robbins PF, Wang X et al. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J Immunol 1998: 161: 6985-92.
14. Mori M, Beatty PG, Graves M, Boucher KM, Milford EL. HLA gene and haplotype frequencies in the North American population: the National Marrow Donor Program Donor Registry. Transplantation 1997: 64: 1017-27.
15. Degiovanni G, Lahaye T, Herin M, Hainaut P, Boon T. Antigenic heterogeneity of a human melanoma tumor detected by autologous CTL clones. Eur J Immunol 1988: 18: 671-6.
16. Murata M, Warren EH, Riddell SR. A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med 2003: 197: 1279-89.
17. Uyttenhove C, Pilotte L, Theate I et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003: 9: 1269-74.
18. Gaugler B, Van den Eynde B, van der Bruggen P et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994: 179: 921-30.
19. Seed B, Aruffo A. Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure. Proc Natl Acad Sci USA 1987: 84: 3365-9.
20. Zarour H, De Smet C, Lehmann F et al. The majority of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pmel17/gp100. J Invest Dermatol 1996: 107: 63-7.
21. Traversari C, van der Bruggen P, Van den Eynde B et al. Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics 1992: 35: 145-52.
22. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995: 182: 689-98.
23. De Plaen E, Lurquin C, Lethe B et al. Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes. Methods 1997: 12: 125-42.
24. Vigneron N, Ooms A, Morel S, Degiovanni G, Van Den Eynde BJ. Identification of a new peptide recognized by autologous cytolytic T lymphocytes on a human melanoma. Cancer Immun 2002: 2: 9.
25. Morel S, Ooms A, Van Pel A et al. A tyrosinase peptide presented by HLA-B35 is recognized on a human melanoma by autologous cytotoxic T lymphocytes. Int J Cancer 1999: 83: 755-9.
26. Vigneron N, Stroobant V, Chapiro J et al. An antigenic peptide produced by peptide splicing in the proteasome. Science 2004: 304: 587-90.
27. Adema GJ, de Boer AJ, Vogel AM, Loenen WA, Figdor CG. Molecular characterization of the melanocyte lineage-specific antigen gp100. J Biol Chem 1994: 269: 20126-33.
28. Rammensee H-G, Bachmann J, Stevanovic S. MHC Ligands and Peptide Motifs. Heidelberg: Springer 1997.
29. Khanna R, Silins SL, Weng Z, Gatchell D, Burrows SR, Cooper L. Cytotoxic T cell recognition of allelic variants of HLA B35 bound to an Epstein-Barr virus epitope: influence of peptide conformation and TCR-peptide interaction. Eur J Immunol 1999: 29: 1587-97.
30. Gauchat-Feiss D, Rufer N, Speiser D, Jeannet M, Roosnek E, Tiercy JM. Heterogeneity of HLA-B35. Oligotyping and direct sequencing for B35 subtypes reveals a high mismatching rate in B35 serologically compatible kidney and bone marrow donor /recipient pairs. Transplantation 1995: 60: 869-73.